Halogen bonding for rational drug design and new drug discovery
文献类型：期刊论文
| 作者 | Lu, Yunxiang1,2; Liu, Yingtao3; Xu, Zhijian3 ; Li, Haiying1,2; Liu, Honglai1,2; Zhu, Weiliang3
|
| 刊名 | EXPERT OPINION ON DRUG DISCOVERY
 |
| 出版日期 | 2012-05 |
| 卷号 | 7期号:5页码:375-383 |
| 关键词 | binding affinity drug design halogen bonding inhibitors |
| ISSN号 | 1746-0441 |
| DOI | 10.1517/17460441.2012.678829 |
| 文献子类 | Review |
| 英文摘要 | Introduction: A large number of drugs and drug candidates in clinical development contain halogen substituents. For a long time, only the steric and lipophilic contributions of halogens were considered when trying to exploit their effects on ligand binding. However, the ability of halogens to form stabilizing interactions, such as halogen bonding, hydrogen bonding and multipolar interactions, in biomolecular systems was revealed recently. Halogen bonding, the non-covalent interaction in which covalently bound halogens interact with Lewis bases, has now been utilized in the context of rational drug design. Areas covered: The purpose of this review is to show how halogen bonding could be used in drug design, and in particular, to stimulate researchers to apply halogen bonding in lead optimization. This review article covers the recent advances relevant to halogen bonding in drug discovery and biological design over the past decade, including database survey of this interaction in protein-ligand complexes, molecular mechanical investigations of halogen bonding in drug discovery and applications of this interaction in the development of halogenated ligands as inhibitors and drugs for protein kinases, serine protease factor Xa, HIV reverse transcriptase and so on. Expert opinion: Halogen bonding should intentionally be used as a powerful tool, comparable with hydrogen bonding, to enhance the binding affinity and also influence the binding selectivity. Rational design of new and potent inhibitors against therapeutic targets through halogen bonding continues to be an exciting area, which will be further elucidated with the combination of various experimental techniques and theoretical calculations in the forthcoming years. |
| WOS关键词 | HIV-1 REVERSE-TRANSCRIPTASE ; PROTEIN-LIGAND COMPLEXES ; X-RAY CRYSTALLOGRAPHY ; SIGMA-HOLE ; NONNUCLEOSIDE INHIBITORS ; BIOLOGICAL RECOGNITION ; MOLECULAR-INTERACTIONS ; CRYSTAL-STRUCTURES ; PI INTERACTIONS ; AROMATIC RINGS |
| 资助项目 | Natural Science Foundation of Shanghai[11ZR1408700] ; National Natural Science Foundation of China[21103047] ; Fundamental Research Funds for the Central Universities of China[00000000] ; MOST[2010DFB73280] ; 973 project[2012CB910403] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000303329500002 |
| 出版者 | INFORMA HEALTHCARE |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/278095]  |
| 专题 | 药物发现与设计中心 |
| 通讯作者 | Lu, Yunxiang |
| 作者单位 | 1.E China Univ Sci & Technol, Key Lab Adv Mat, Shanghai 200237, Peoples R China; 2.E China Univ Sci & Technol, Dept Chem, Shanghai 200237, Peoples R China; 3.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Lu, Yunxiang,Liu, Yingtao,Xu, Zhijian,et al. Halogen bonding for rational drug design and new drug discovery[J]. EXPERT OPINION ON DRUG DISCOVERY,2012,7(5):375-383. |
| APA | Lu, Yunxiang,Liu, Yingtao,Xu, Zhijian,Li, Haiying,Liu, Honglai,&Zhu, Weiliang.(2012).Halogen bonding for rational drug design and new drug discovery.EXPERT OPINION ON DRUG DISCOVERY,7(5),375-383. |
| MLA | Lu, Yunxiang,et al."Halogen bonding for rational drug design and new drug discovery".EXPERT OPINION ON DRUG DISCOVERY 7.5(2012):375-383. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。